The role of PTEN as a PI(3,4)P2 lipid phosphatase in Class I phosphoinositide 3-kinase signalling

Name: Anna Jadwiga Kielkowska Dissertation title: The role of PTEN as a PI(3,4)P2 lipid phosphatase in Class I phosphoinositide 3-kinase signalling Abstract Class I phosphoinositide 3-kinases (Class I PI3Ks) are essential players involved in the signalling events in the cell and are critical promoters of cellular growth, survival and metabolism. Once activated by environmental stimuli such as growth factors, cytokines or antigens, they exert their catalytic activity by phosphorylating phosphatidylinositol (4,5)-bisphosphate (PI(4,5)P2) to yield a second messenger - PI(3,4,5)P3. Unrestrained PI(3,4,5)P3 signalling has been classically associated with hyperactivation of the Class I PI3K/AKT pathway and has been shown to be a molecular trigger of many pathophysiologies in humans, including autoimmune disorders, respiratory diseases and cancer. To date, two classes of lipid phosphatases SHIP1/2 and PTEN have been reported, which dephosphorylate PI(3,4,5)P3 on positions 5’ and 3’ of the inositol ring to generate PI(3,4)P2 and PI(4,5)P2 respectively, and thus quench Class I PI3K signalling. Moreover, PI(3,4)P2 levels in the cell are regulated by two important lipid 4-phosphatases - INPP4A/B. While the role of PTEN as a tumour suppressor is well established, functions of SHIP1/2 and INPP4A/B are just starting to emerge. A major barrier to progress in this field has been the lack of high quality measurements of PI(3,4)P2, to assess the impact it may have on shaping cellular behaviour. This dissertation summarises the work performed to develop a novel, HPLC-ESI MS/MS based method, in order to measure the product of PI(3,4,5)P3 5-dephosphorylation, PI(3,4)P2, separated from its more abundant regioisomer in cells - PI(4,5)P2. This and an existing HPLC-ESI MS/MS method for measuring PI(3,4,5)P3, have enabled us to describe the fluxes through Class I PI3K-controlled PI(3,4,5)P3 generation and its subsequent 3- and 5- dephosphorylation pathways in human mammary epithelial cells (Mcf10a) stimulated with epidermal growth factor (EGF). By means of genetic suppression of PTEN and INPP4B, we revealed an unexpectedly high level of PI(3,4)P2 that accumulates in EGF-stimulated PTEN-INPP4B-KO Mcf10a cells. Further, an in vitro biochemical assay suggested a novel role for PTEN as a direct PI(3,4)P2 3-phosphatase in Mcf10a cells. This important observation was supported by in sillico phosphatidylinositol lipid modelling of the relevant pathways. In an effort to understand its potential physiological significance, we demonstrated that PI(3,4)P2 accumulation correlates with the ability of genetically modified Mcf10a cells to form gelatin-degrading invadopodia. Finally, we used a mouse prostate cancer model to show PTEN’s importance in controlling PI(3,4)P2 levels in vivo, pointing to a potential role for PI(3,4)P2 in PTEN-dependent tumourigenesis. I hope that the work described in this dissertation will contribute to the current knowledge of phosphatidylinositol lipid biology in the context of Class I PI3K signalling and will simulate future efforts to gain an in-depth understanding of the roles of PTEN and PI(3,4)P2 in cellular physiology

A Semisynthetic Fluorescent Sensor Protein for Glutamate

We report the semisynthesis of a fluorescent glutamate sensor protein on cell surfaces. Sensor excitation at 547 nm yields a glutamate-dependent emission spectrum between 550 and 700 nm that can be exploited for ratiometric sensing. On cells, the sensor displays a ratiometric change of 1.56. The high sensitivity toward glutamate concentration changes of the sensor and its exclusive extracellular localization make it an attractive tool for glutamate sensing in neurobiology

PLEKHS1 drives PI3Ks and remodels pathway homeostasis in PTEN-null prostate

The PIP3/PI3K network is a central regulator of metabolism and is frequently activated in cancer, commonly by loss of the PIP3/PI(3,4)P2 phosphatase, PTEN. Despite huge research investment, the drivers of the PI3K network in normal tissues and how they adapt to overactivation are unclear. We find that in healthy mouse prostate PI3K activity is driven by RTK/IRS signaling and constrained by pathway feedback. In the absence of PTEN, the network is dramatically remodeled. A poorly understood YXXM- and PIP3/PI(3,4)P2-binding PH domain-containing adaptor, PLEKHS1, became the dominant activator and was required to sustain PIP3, AKT phosphorylation, and growth in PTEN-null prostate. This was because PLEKHS1 evaded pathway-feedback and experienced enhanced PI3K- and Src-family kinase-dependent phosphorylation of Y258XXM, eliciting PI3K activation. hPLEKHS1 mRNA and activating Y419 phosphorylation of hSrc correlated with PI3K pathway activity in human prostate cancers. We propose that in PTEN-null cells receptor-independent, Src-dependent tyrosine phosphorylation of PLEKHS1 creates positive feedback that escapes homeostasis, drives PIP3 signaling, and supports tumor progression

Lysophosphatidylinositol-acyltransferase-1 (LPIAT1) is required to maintain physiological levels of PtdIns and PtdInsP(2) in the mouse.

We disrupted the gene encoding lysophosphatidylinositol-acyltransferase-1 (LPIAT1) in the mouse with the aim of understanding its role in determining cellular phosphoinositide content. LPIAT1(-/-) mice were born at lower than Mendelian ratios and exhibited a severe developmental brain defect. We compared the phospholipid content of livers and brains from LPIAT1(-/-) and LPIAT1(+/+) littermates by LC-ESI/MS. In accord with previous studies, the most abundant molecular species of each phosphoinositide class (PtdIns, PtdInsP, PtdInsP2 and PtdInsP3) possessed a C38∶4 complement of fatty-acyl esters (C18∶0 and C20∶4 are usually assigned to the sn-1 and sn-2 positions, respectively). LPIAT1(-/-) liver and brain contained relatively less of the C38∶4 species of PtdIns, PtdInsP and PtdInsP2 (dropping from 95-97% to 75-85% of the total species measured for each lipid class) and relatively more of the less abundant species (PtdInsP3 less abundant species were below our quantification levels). The increases in the less abundant PtdIns and PtdInsP2 species did not compensate for the loss in C38∶4 species, resulting in a 26-44% reduction in total PtdIns and PtdInsP2 levels in both brain and liver. LPIAT1(-/-) brain and liver also contained increased levels of C18∶0 lyso-PtdIns (300% and 525% respectively) indicating a defect in the reacylation of this molecule. LPIAT1(-/-) brain additionally contained significantly reduced C38∶4 PC and PE levels (by 47% and 55% respectively), possibly contributing to the phenotype in this organ. The levels of all other molecular species of PC, PE, PS and PA measured in the brain and liver were very similar between LPIAT1(-/-) and LPIAT1(+/+) samples. These results suggest LPIAT1 activity plays a non-redundant role in maintaining physiological levels of PtdIns within an active deacylation/reacylation cycle in mouse tissues. They also suggest that this pathway must act in concert with other, as yet unidentified, mechanisms to achieve the enrichment observed in C38∶4 molecular species of phosphoinositides

A Semisynthetic Fluorescent Sensor Protein for Glutamate

We report the semisynthesis of a fluorescent glutamate sensor protein on cell surfaces. Sensor excitation at 547 nm yields a glutamate-dependent emission spectrum between 550 and 700 nm that can be exploited for ratiometric sensing. On cells, the sensor displays a ratiometric change of 1.56. The high sensitivity toward glutamate concentration changes of the sensor and its exclusive extracellular localization make it an attractive tool for glutamate sensing in neurobiology

Effect of LPIAT1 knockout on brain and liver lyso-phospholipid molecular species.

<p>Brains (<b>A</b>) or livers (<b>B</b>) from 13 day old littermates expressing (LPIAT1^+/+ (WT)) or lacking (LPIAT1^−/− (KO)) LPIAT1 were ground, homogenized and lipids extracted from 0.5 mg wet weight as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0058425#s2" target="_blank">Materials and Methods</a>. Lyso-phospholipids were targeted and were detected by MRM mass spectrometric anaylsis as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0058425#s2" target="_blank">Materials and Methods</a>. Data are expressed as moles/mg protein, normalized to relevant internal standards. Shown are mean ± SD, n = 4 for both WT and KO. Data were analyzed by T-test. *p≤0.05, **p≤0.005.</p

Generation of LPIAT1 knockout first mice.

<p>(<b>A</b>) Schematic representation of LPIAT^{tm1a(KOMP)Wtsi} gene targeting vector, constructed by the High throughput gene targeting group at the Sanger Center as a ‘knock-out first’ allele that abrogates expression of the targeted allele. Shown are expected enzymatic digest fragments for EcoRI, HindIII and AseI digests of the correctly targeted allele, which were confirmed by Southern analysis of three ES cell clones and WT BL6 genomic DNA control using a [³²P]-oligonucleotide probe to a 600bp region of the Neomycin gene within the targeting cassette (<b>B</b>). (<b>C</b>) Genotyping of mice was performed by PCR amplification to identify the presence of LPIAT1 WT allele (+) and/or targeted KO allele (−) from LPIAT1^+/−, LPIAT1^+/+ and LPIAT1^−/− mice. (<b>D</b>) Western blot analysis was performed on 50 µg wet weight brain tissue from three pairs of LPIAT1^+/+ (WT) and LPIAT1^−/− (KO) 13 day old littermates as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0058425#s2" target="_blank">Materials and Methods</a>. Shown is a representative immunoblot, with the arrow indicating the position of LPIAT1 protein.</p